{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "BIOCELTIX S.A.  ZY -,10", "longName": "Bioceltix S.A.", "messageBoardId": "finmb_599022432", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": 1.5479877, "regularMarketPrice": 16.4, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1638946800000, "priceHint": 2, "epsTrailingTwelveMonths": -0.55, "sharesOutstanding": 3427320, "fiftyDayAverage": 10.6554, "fiftyDayAverageChange": 5.7445993, "fiftyDayAverageChangePercent": 0.5391256, "twoHundredDayAverage": 8.4143, "twoHundredDayAverageChange": 7.9856997, "twoHundredDayAverageChangePercent": 0.9490629, "marketCap": 56208048, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "regularMarketChange": 0.25, "regularMarketTime": 1683875702, "regularMarketDayHigh": 16.4, "regularMarketDayRange": "16.4 - 16.4", "regularMarketDayLow": 16.4, "regularMarketVolume": 10, "regularMarketPreviousClose": 16.15, "bid": 16.0, "ask": 17.55, "fullExchangeName": "Frankfurt", "financialCurrency": "PLN", "regularMarketOpen": 16.4, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 10.34, "fiftyTwoWeekLowChangePercent": 1.7062707, "fiftyTwoWeekRange": "6.06 - 16.45", "fiftyTwoWeekHighChange": -0.050001144, "fiftyTwoWeekHighChangePercent": -0.003039583, "fiftyTwoWeekLow": 6.06, "fiftyTwoWeekHigh": 16.45, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "XI3.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building III", "address2": "Bierutowska 57-59 Street", "city": "Wroclaw", "zip": "51-317", "country": "Poland", "phone": "48 71 880 8771", "fax": "48 71 734 5509", "website": "https://bioceltix.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Grzegorz  Ostropolski", "title": "Chief Exec. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Lukasz  Bzdzion", "title": "Pres of the Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Andrij  Wlach", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Pawel  Wielgus", "title": "Member of the Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Jakub  Grzesiak", "title": "Technology Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}